Please login to the form below

Not currently logged in
Email:
Password:

Celesio still has claws in Protek despite delays

The EU's largest drug distributor, Celesio, is continuing to pursue a majority stake in Russian drug company Protek, despite a delay in the process

German-headquartered Celesio, the EU's largest drug distributor, is continuing to pursue a majority stake in Russian drug company Protek, despite a delay in the process, according to CEO Fritz Oesterle.

Oesterle said the delay was due to uncertainty concerning a possible nationalisation of one of Russia's top three pharmaceuticals companies, of which Protek is one, before the Russian elections earlier this month.

The speculation, although now diminished, now means that no deal would complete this year, according to Oesterle, who added that the transaction was not in jeopardy.

He said in a press statement on 12 December that if the company had the chance to get more information in the next two months then it would seize it.

When Celesion revealed the deal in October, it said it expected negotiations to be completed by mid-December. Oesterle also said Celesio was on the lookout for acquisitions in eastern Europe in 2008.

16th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics